Luminopia Funding Round

11/11/2022

Venture Equity

$5,700,000

Seed

The company will be using the funding for a staged rollout of its lead product for amblyopia to pediatric ophthalmologists starting this month, before expanding to a broader launch in the second half of 2023.

Private & Independent

Healthcare Services

955 Massachusetts Ave 335
Cambridge, MA 02139
USA

Around 15 million Americans suffer from vision loss caused by deficiencies in the brain, instead of any structural issues with the eyes. Traditional therapeutic modalities are unable to properly target and treat these deficits, leaving a significant unmet need. By harnessing the latest in digital technology, we're creating an entirely new category of medicines to address these conditions. We develop software products that generate therapeutic visual stimuli and deliver them to the patient through a virtual reality headset, using the eyes to stimulate the brain. The success of our amblyopia therapeutic provides proof-of-concept for our broader platform.